Report really just highlights the obvious that guidance has slipped & business/revenue, cash positive are dependent on managements ability to secure new partnerships then deliver the objectives on each - it does also move to that while managements ability to secure deals is at the crux it is always at the hands of big pharma so direct outcomes &/or timeframes are really outside of the companys control.
Roche expected soon, Pfizer sounded not quite as close as whats been previously posted, AZ no idea they've been evaluating that since end '11 ? I'm not sure why they'e highlighted milestones 2013 financial year as i thought there was confidence early this year ? and 2013 FY would be post June 30th ?
Still banging on about management calling 3 new deals a year & cash sustainibility '13 hahah - keep calling it & you have to get it right some day i guess :-)
Missed guidance lowered their target marginally from 5.6c to 5.4c since last report.
PYC Price at posting:
2.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)